(IPCI) Announces Successful Bioequivalence Results, Rexista™ Oxycodone XR

TORONTO, Jan. 14, 2016  — Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that pivotal bioequivalence trials of the Company’s Rexista™ Oxycodone XR (abuse deterrent oxycodone hydrochloride) extended release tablets, dosed under fasted and fed conditions, had demonstrated bioequivalence to Oxycontin® (oxycodone hydrochloride) extended release tablets as manufactured and sold in the United States by Purdue Pharma LP. The study design was based on United States Food and Drug Administration (“FDA”) recommendations and compared the lowest and highest strengths of exhibit batches of the Company’s Rexista™ Oxycodone XR to the same strengths of Oxycontin®. The results show that the ratios of the pharmacokinetic metrics, C_max, AUC_0-t and AUC_0-f  for Rexista™ vs. Oxycontin®, are within the interval of 80% – 125% required by the FDA with a confidence level exceeding 90%.

The Company had earlier announced, in March 2015, that topline data results of three definitive Phase I pharmacokinetic clinical trials (single dose fasting, single dose steady-state fasting, and single dose fed), conducted on pilot batches of the Company’s Rexista™ Oxycodone XR, all met the FDA bioequivalence criteria when compared to the existing branded drug Oxycontin®.

The Company had also earlier announced, in May 2015, that the FDA had provided the Company with notification regarding its Investigational New Drug Application (“IND”) submission for Rexista™ Oxycodone XR.  The notification from the FDA had stated that the Company would not be required to conduct Phase III studies if bioequivalence to Oxycontin® was demonstrated.

Having now demonstrated such bioequivalence for its Rexista™ Oxycodone XR product to be marketed upon FDA approval, the Company intends to complete the regulatory filing requirements and file a New Drug Application (“NDA”) for Rexista™ Oxycodone XR with the FDA within the next 6 months in accordance with the NDA 505(b)(2) regulatory pathway.  There can be no assurance that the FDA will ultimately approve the NDA for the sale of Rexista™ Oxycodone XR in the U.S. market, or that it will ever be successfully commercialized.

“We take great pride in being the first pharmaceutical company, to the best of our knowledge, to have demonstrated bioequivalence in both fasted and fed conditions to the brand reference drug Oxycontin®.  This enables us to accelerate the development and commercialization of our abuse deterrent Rexista™ Oxycodone XR product candidate without the need for costly and time-consuming Phase III efficacy trials,” stated Dr. Isa Odidi, CEO and co-founder of Intellipharmaceutics. “We look forward to filing an NDA within the next six months, which we hope will lead to a positive contribution in addressing an unmet need in opioid abuse and addiction.”

Rexista™ Oxycodone XR

Rexista™ Oxycodone XR is the Company’s non-generic extended release formulation intended for the management of moderate to severe pain when an around-the-clock analgesic is required. The formulation is intended to present a significant barrier to tampering when subjected to various forms of anticipated physical and chemical manipulation commonly used by abusers. It is also designed to prevent dose dumping when inadvertently or intentionally co-administered with alcohol. In addition, when crushed or pulverized and hydrated, the proposed extended release formulation is designed to coagulate instantaneously and entrap the drug in a viscous hydrogel, which is intended to prevent syringing, injecting or snorting.

About Intellipharmaceutics

Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. The Company’s patented Hypermatrix™ technology is a multidimensional controlled-release drug delivery platform that can be applied to the efficient development of a wide range of existing and new pharmaceuticals. Based on this technology platform, Intellipharmaceutics has developed several drug delivery systems and a pipeline of products (our dexmethylphenidate hydrochloride extended-release capsules for the 15 and 30 mg strengths which received final FDA approval) and product candidates in various stages of development, including Abbreviated New Drug Applications (“ANDAs “) filed with the FDA (and one Abbreviated New Drug Submission (“ANDS”)  filed with Health Canada) in therapeutic areas that include neurology, cardiovascular, gastrointestinal tract, diabetes and pain.

Intellipharmaceutics also has NDA 505(b)(2) specialty drug product candidates in its development pipeline. These include Rexista™ Oxycodone XR, an abuse deterrent oxycodone based on its proprietary nPODDDS™ novel Point Of Divergence Drug Delivery System and PODRAS™ Paradoxical OverDose Resistance Activating System, and Regabatin™ XR pregabalin extended-release capsules. Our current development effort is increasingly directed towards improved difficult-to-develop controlled-release drugs which follow an NDA 505(b)(2) regulatory pathway. The Company has increased its research and development emphasis towards new product development, facilitated by the 505(b)(2) regulatory pathway, by advancing the product development program for both Rexista™ and Regabatin™.  The 505(b)(2) pathway (which relies in part upon the approving agency’s findings for a previously approved drug) both accelerates development timelines and reduces costs in comparison to NDAs for new chemical entities. An advantage of our strategy for development of NDA 505(b)(2) drugs is that our product candidates can, if approved for sale by the FDA, potentially enjoy an exclusivity period which may provide for greater commercial opportunity relative to the generic ANDA route.

Certain statements in this document constitute “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and/or “forward-looking information” under the Securities Act (Ontario). These statements include, without limitation, statements expressed or implied regarding our plans, goals and milestones, status of developments or expenditures relating to our business, plans to fund our current activities, statements concerning our partnering activities, health regulatory submissions, strategy, future operations, future financial position, future sales, revenues and profitability, projected costs, and market penetration. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “plans to,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” “intends,” “could,” or the negative of such terms or other comparable terminology. We made a number of assumptions in the preparation of our forward-looking statements. You should not place undue reliance on our forward-looking statements, which are subject to a multitude of known and unknown risks and uncertainties that could cause actual results, future circumstances or events to differ materially from those stated in or implied by the forward-looking statements. Risks, uncertainties and other factors that could affect our actual results include, but are not limited to, the effects of general economic conditions, securing and maintaining corporate alliances, our estimates regarding our capital requirements, and the effect of capital market conditions and other factors, including the current status of our product development programs, on capital availability, the potential dilutive effects of any future financing and the expected use of any proceeds from any offering of our securities, our ability to maintain compliance with the continued listing requirements of the principal markets on which our securities are traded, our programs regarding research, development and commercialization of our product candidates, the timing of such programs, the timing, costs and uncertainties regarding obtaining regulatory approvals to market our product candidates and the difficulty of predicting the timing and results of any product launches, and the timing and amount of any available investment tax credits, the actual or perceived benefits to users of our drug delivery technologies, products and product candidates as compared to others, our ability to establish and maintain valid and enforceable intellectual property rights in our drug delivery technologies, products and product candidates, the scope of protection provided by intellectual property for our drug delivery technologies, products and product candidates, the actual size of the potential markets for any of our products and product candidates compared to our market estimates, our selection and licensing of products and product candidates, our ability to attract distributors and collaborators with the ability to fund patent litigation and with acceptable development, regulatory and commercialization expertise and the benefits to be derived from such collaborative efforts, sources of revenues and anticipated revenues, including contributions from distributors and collaborators, product sales, license agreements and other collaborative efforts for the development and commercialization of product candidates, our ability to create an effective direct sales and marketing infrastructure for products we elect to market and sell directly, the rate and degree of market acceptance of our products, delays that may be caused by changing regulatory requirements, the difficulty in predicting the timing of regulatory approval and the timing of launch of competitive products, the difficulty of predicting the impact of competitive products on volume and pricing, the inability to forecast wholesaler demand and/or wholesaler buying patterns, the seasonal fluctuation in the numbers of prescriptions written for our dexmethylphenidate hydrochloride extended-release capsules which may produce substantial fluctuations in revenues, the timing and amount of insurance reimbursement for our products, changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products, the success and pricing of other competing therapies that may become available, our ability to retain and hire qualified employees, the availability and pricing of third party sourced products and materials, difficulties or delays in manufacturing, the manufacturing capacity of third-party manufacturers that we may use for our products, the successful compliance with FDA, Health Canada and other governmental regulations applicable to the Company and its third party manufacturers’ facilities, products and/or businesses, difficulties, delays or changes in the FDA approval process or test criteria for ANDAs and NDAs and risks associated with cyber-security and vulnerability of the Company’s digital information and the digital information of the Company’s commercialization partner(s). Additional risks and uncertainties relating to the Company and our business can be found in the “Risk Factors” section of our latest annual information form, our latest Form 20-F, and our latest Form F-3 (including any documents forming a part thereof or incorporated by reference therein), as well as in our reports, public disclosure documents and other filings with the securities commissions and other regulatory bodies in Canada and the U.S., which are available on www.sedar.com and www.sec.gov. The forward-looking statements reflect our current views with respect to future events and are based on what we believe are reasonable assumptions as of the date of this document, and we disclaim any intention and have no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT:

Company Contact:

Intellipharmaceutics International Inc.
Domenic Della Penna
Chief Financial Officer
416-798-3001 ext 106
investors@intellipharmaceutics.com

Investor Contact:

ProActive Capital
Kirin Smith
646-863-6519
ksmith@proactivecapital.com

(AMS) Announces Permanent Financing Package

AMERICAN SHARED HOSPITAL SERVICES (NYSE MKT:AMS), a leading provider of turnkey technology solutions for advanced radiosurgical and radiation therapy services, announced today that it has entered into a definitive agreement for the permanent financing, subject to regulatory approval and standard conditions precedent, of its proton therapy center now under construction at UF (University of Florida) Health Cancer Center – Orlando Health in Florida. This center, which will employ the MEVION S250 proton therapy system, is expected to begin treating patients in April of this year.

Chairman and Chief Executive Officer Ernest A. Bates, M.D., said, “This financing agreement is an important milestone in the development of AMS’ proton business, a business we believe represents an extraordinary growth opportunity for our company. We have guided this initial project from its inception through delivery and installation of the MEVION S250 system, obtained permanent financing, and look forward to Orlando Health initiating patient treatments soon. This demonstrates that we have the resources and know-how to get these complex projects done, an important consideration for other hospitals around the country that have expressed interest in partnering with AMS to develop proton centers of their own. We believe that the clinical advantages of proton therapy in the treatment of a wide range of cancers will support rapid growth in the application of this advanced therapeutic technology, and we are convinced that AMS will be a significant beneficiary.”

About AMS

American Shared Hospital Services provides turnkey technology solutions for advanced radiosurgical and radiation therapy services. AMS is the world leader in providing Gamma Knife radiosurgery equipment, a non-invasive treatment for malignant and benign brain tumors, vascular malformations and trigeminal neuralgia (facial pain). The Company also offers the latest IGRT and IMRT systems, as well as its proprietary Operating Room for the 21st Century^SM concept. AMS owns a common stock investment in Mevion Medical Systems, Inc., developer of the compact MEVION S250 Proton Therapy System.

About Orlando Health

Orlando Health is a $2.3 billion not-for-profit health care organization and a community-based network of physician practices, hospitals, and outpatient care centers throughout Central Florida. The organization includes Orlando Health Physician Group and Physician Associates, two of the largest multi-specialty practices in Central Florida, ownership in an outpatient surgery center, and eight wholly-owned or affiliated hospitals. An Orlando Health subsidiary holds a 51 percent interest in an entity operating five outpatient imaging centers.

Orlando Health is home to the area’s only Level One Trauma Centers for adults and pediatrics and is a statutory teaching hospital system that offers both specialty and community hospitals. They are: Orlando Regional Medical Center; Dr. P. Phillips Hospital; South Seminole Hospital; Health Central Hospital, the Arnold Palmer Medical Center, which consists of Arnold Palmer Hospital for Children and Winnie Palmer Hospital for Women & Babies; the UF Health Cancer Center – Orlando Health, South Lake Hospital (50 percent affiliation); and St. Cloud Regional Medical Center (20 percent affiliation). Areas of clinical excellence are heart and vascular, cancer care, neurosciences, surgery, pediatric orthopedics and sports medicine, neonatology, and women’s health.

More than 2,000 physicians have privileges at Orlando Health, which is also one of the area’s largest employers with more than 15,000 employees who support our philosophy of providing high quality care and service that revolves around patients’ needs. We prove this everyday with over 100,000 inpatient admissions and nearly 900,000 outpatient visits each year. In all, Orlando Health serves 1.8 million Central Florida residents and more than 4,500 international patients annually. Additionally, Orlando Health provides nearly $235 million in support of community health needs. More information can be found at http://www.orlandohealth.com.

Safe Harbor Statement

This press release may be deemed to contain certain forward-looking statements with respect to the financial condition, results of operations and future plans of American Shared Hospital Services, which involve risks and uncertainties including, but not limited to, the risks of the Gamma Knife and radiation therapy businesses, the risks of developing The Operating Room for the 21st Century program, the risks of investing in a development-stage company, Mevion Medical Systems, Inc., and the risks of the timing, financing, and operations of the Company’s proton therapy business. Further information on potential factors that could affect the financial condition, results of operations and future plans of American Shared Hospital Services is included in the filings of the Company with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2014, its quarterly reports on Form 10-Q for the three months ended March 31, 2015, June 30, 2015, and September 30, 2015, and the definitive Proxy Statement for the Annual Meeting of Shareholders held on June 16, 2015.

(COYN) Hosts Law Enforcement Officials and Community Leaders at NY-NJ Launch Event

DALLAS, Jan. 14, 2016  — COPsync, Inc. (NASDAQ:COYN), which operates the nation’s largest law enforcement in-car information sharing and communication network, and the COPsync911 threat-alert service for schools, government buildings, hospitals and other potentially at-risk facilities, hosted a meeting January 7, 2016 in New York City to announce plans to launch COPsync’s safety and security solutions for schools, law enforcement agencies and municipalities across the states of New York and New Jersey.

COPsync Chief Executive Officer Ronald A. Woessner showcased the lifesaving COPsync Network and COPsync911 technology to a select audience of C-level executives, law enforcement and education officials, and political leaders, including representatives from the New York State Troopers Police Benevolent Association, the New York judiciary, and U.N. Ambassador Jack Brewer.

Mr. Woessner described how the COPsync Network provides what is missing in today’s law enforcement – having the ability to communicate in real-time about crimes in progress and share mission-critical information across agency jurisdictional boundaries, all for the purpose of keeping law enforcement officers safer and enabling them to interdict crime and criminal behavior more effectively. He also highlighted how COPsync’s companion product, COPsync911, fulfills communities’ demands for safer schools by informing the closest officers of a school threat faster and equipped with up-to-the-minute situational information unfolding at the scene.

Describing the event, Ambassador Jack Brewer stated, “The meeting was an instrumental step in the COPsync expansion efforts in the Northeast, and it will be exciting to see COPsync expand across the length and breadth of the United States. The COPsync Network protects police officers and gives them the tools to do their jobs more effectively, while COPsync911 protects at-risk facilities, schools and schoolchildren, and provides a measure of liability protection for school administrators and school boards because they have taken steps to provide the safest environment for the students and staff.”

“We are honored to have met with political leaders and law enforcement officials who share our vision and recognize the capabilities of the COPsync Network in protecting law enforcement officers, children and communities,” commented Mr. Woessner. “We look forward to continuing to work with all involved parties to further expand the Company’s customer footprint in municipalities, schools and law enforcement agencies across the great states of New York and New Jersey and throughout the country.”

COPsync’s solutions are being supported and endorsed by a growing number of strategic alliances throughout the nation, which include The Blue Alert Foundation, developer of the Blue Alert system, which provides law enforcement officers a means to become aware of threats made against them. The Company also is actively expanding its footprint in various targeted territories with the garnered support of several celebrity endorsers, brand ambassadors and community leaders as well as through ongoing launch events and awareness campaigns to be announced soon.

About COPsync, Inc.

COPsync, Inc. (COYN) is a technology company that improves communication between and among law enforcement officers and agencies from differing jurisdictions to help them prevent and respond more quickly to crime. The COPsync Network connects law enforcement officers and agencies to a common communications system, which gives officers instant access to actionable, mission-critical data and enables them to share information and communicate in real-time with other officers and agencies, even those hundreds and thousands of miles away. The Network’s companion COPsync911 threat-alert system, enables schools, courts, hospitals, government buildings, energy, telecommunications and other potentially at-risk facilities to automatically and silently send threat alerts directly to local law enforcement officers in their patrol cars in the event of a crisis, thereby speeding first responder response times and saving minutes when seconds count. The COPsync Network saves officer and citizen lives, reduces unsolved crimes and assists in apprehending criminals and interdicting criminal behavior — through such features as a nationwide officer safety alert system, GPS/auto vehicle location and distance-based alerts for crimes in progress, such as school crisis situations, child abductions, bank robberies and police pursuits. The COPsync Network also eliminates manual processes and increases officer productivity by enabling officers to write electronic tickets, accident reports, DUI forms, arrest forms and incident and offense reports. The company also sells VidTac®, an in-vehicle, software-driven video system for law enforcement. Visit www.copsync.com and www.copsync911.com for more information.

Contact:
For COPsync:
Ronald A. Woessner
Chief Executive Officer
972-865-6192
invest@copsync.com

Media:
Fred Sommer
Senior Consultant
Investor Relations
Ascendant Partners, LLC.
732-410-9810
fred@ascendantpartnersllc.com

(LEI) Schedules Conference Call To Discuss Planned Mid-Continent Acquisition

HOUSTON, Jan. 14, 2016  — Lucas Energy, Inc. (NYSE MKT: LEI) (“Lucas” or the “Company”) announced today that is has scheduled a conference call to discuss the recent announcement of the proposed acquisition of oil and natural gas properties in the Hunton play in the Mid-Continent region in addition to the new strategic direction and rebranding of the Company.  The conference call is scheduled for 11:00 a.m. Eastern Time (10:00 a.m. Central Time) on Thursday, January 21, 2016.  There will be an accompanying slide presentation posted on the Company’s website just prior to the call.  Investors may participate by phone or via audio webcast.

About Lucas Energy, Inc.

Lucas Energy (NYSE MKT: LEI) is engaged in the development of crude oil and natural gas in the Austin Chalk and Eagle Ford formations in South Texas. Based in Houston, Lucas’s management team is committed to building a platform for growth and the development of its five million barrels of proved Eagle Ford and other oil reserves while continuing its focus on operating efficiencies and cost control.

Forward Looking Statements

In addition to historical information contained herein, this news release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, subject to various risks and uncertainties that could cause the Company’s actual results to differ materially from those in the “forward-looking” statements. Although Lucas believes that the expectations reflected in such forward-looking statements are reasonable, these statements involve risks and uncertainties that may cause actual future activities and results to be materially different from those suggested or described in this news release. These risks and uncertainties include, but are not limited to: the occurrence of any event, change or other circumstances that could give rise to the termination of the asset purchase agreement; and the inability to complete the transaction due to the failure to satisfy any of the conditions to completion of the transaction. These also include risks inherent in natural gas and oil drilling and production activities, including risks of fire, explosion, blowouts, pipe failure, casing collapse, unusual or unexpected formation pressures, environmental hazards, and other operating and production risks, which may temporarily or permanently reduce production or cause initial production or test results to not be indicative of future well performance or delay the timing of sales or completion of drilling operations; delays in receipt of drilling permits; risks with respect to natural gas and oil prices, a material decline which could cause Lucas to delay or suspend planned drilling operations or reduce production levels; risks relating to the availability of capital to fund drilling operations that can be adversely affected by adverse drilling results, production declines and declines in natural gas and oil prices; risks relating to unexpected adverse developments in the status of properties; risks relating to the absence or delay in receipt of government approvals or fourth party consents; and other risks described in Lucas’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other filings with the SEC, available at the SEC’s website at www.sec.gov. Investors are cautioned that any forward-looking statements are not guarantees of future performance and actual results or developments may differ materially from those projected. The forward-looking statements in this press release are made as of the date hereof. The Company takes no obligation to update or correct its own forward-looking statements, except as required by law, or those prepared by third parties that are not paid for by the Company. The Company’s SEC filings are available at http://www.sec.gov.

Important Information

In connection with the planned acquisition described above, Lucas currently intends to file a registration statement and a proxy statement with the Securities and Exchange Commission (the “SEC”). This communication is not a substitute for any proxy statement, registration statement, proxy statement/prospectus or other document Lucas may file with the SEC in connection with the proposed transaction. Prospective investors are urged to read the registration statement and the proxy statement, when filed as they will contain important information. Any definitive proxy statement(s) (if and when available) will be mailed to stockholders of Lucas. Prospective investors may obtain free copies of the registration statement and the proxy statement, when filed, as well as other filings containing information about Lucas, without charge, at the SEC’s website (www.sec.gov). Copies of Lucas’s SEC filings may also be obtained from Lucas without charge at Lucas’ website (www.lucasenergy.com) or by directing a request to Lucas at (713) 528-1881. This document does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

INVESTORS SHOULD READ THE PROXY STATEMENT AND OTHER DOCUMENTS TO BE FILED WITH THE SEC CAREFULLY BEFORE MAKING A DECISION CONCERNING THE TRANSACTION.

Participants in Solicitation

Lucas and its directors and executive officers and other members of management and employees are potential participants in the solicitation of proxies in respect of the proposed transaction. Information regarding Lucas’s directors and executive officers is available in Lucas’s Annual Report on Form 10-K for the year ended March 31, 2015, filed with the SEC on July 14, 2015 and Lucas’s definitive proxy statement on Schedule 14A, filed with the SEC on February 9, 2015. Additional information regarding the interests of such potential participants will be included in the registration statement and proxy statement to be filed with the SEC by Lucas in connection with the proposed transaction and in other relevant documents filed by Lucas with the SEC. These documents can be obtained free of charge from the sources indicated above. Additional information regarding the participants in the proxy solicitations and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the proxy statement and other relevant materials to be filed with the SEC when they become available.

Contact:
Carol Coale / Ken Dennard
Dennard Lascar Associates, LLC
(713) 529-6600
ccoale@dennardlascar.com
ken@dennardlascar.com
http://www.dennardlascar.com

(LAYN) Layne Christensen Appoints Alan P. Krusi to its Board of Directors

THE WOODLANDS, Texas, Jan. 13, 2016  — Layne Christensen (NASDAQ: LAYN) (“Layne”) today announced that Mr. Alan P. Krusi has been appointed to its Board of Directors, effective January 15, 2016.

Mr. Krusi was President of Strategic Development at AECOM Technology Corporation, a global provider of professional technical and management support services, from 2008 until 2015. As head of Strategic Development, he headed the firm’s mergers and acquisitions program and was a member of the AECOM Executive Management Team. He also oversaw strategic planning and enterprise risk management at various times.  From 2003 to 2008, Mr. Krusi was President and Chief Executive Officer of Earth Tech, Inc., a subsidiary of Tyco International, a global provider of consulting, engineering, construction and operational services of water treatment facilities. He was responsible for the company’s overall growth strategy and operational performance, including investments in the firm’s developed, owned, and operated water treatment plants.

Prior to joining Earth Tech, Inc., Mr. Krusi was President of the Construction Services Division of URS Corporation, which included both the largest U.S. construction management firm and one of the top U.S. environmental remediation contractors.  Mr. Krusi joined URS in 1999 through the merger with Dames & Moore Group where he spent over 15 years as a senior manager. Mr. Krusi currently serves on the Board of publicly-traded Comfort Systems USA, Alacer Gold Corporation and Blue Earth, Inc.

Michael J. Caliel, Layne’s President and CEO, commented, “We are delighted that Alan Krusi has agreed to join the Layne Board of Directors. Alan brings to our Board nearly four decades of executive leadership and corporate development experience in our core industries, including global water management, which aligns itself extremely well with our water focused strategy. With his many accomplishments and his extensive strategic, financial and corporate governance expertise, the Board of Directors and the management team look forward to his contributions to the organization.”

About Layne

Layne is a global solutions provider to the world of essential natural resources—water, minerals and energy. We offer innovative, sustainable products and services with an enduring commitment to safety, excellence and integrity.

Contacts

J. Michael Anderson
Chief Financial Officer
281-475-2694
michael.anderson@layne.com

Dennard Lascar Associates
Jack Lascar
713-529-6600
jlascar@dennardlascar.com

(RRM) Fashion One Television Upgrades Media Services Contract With RR Media

Managing and Delivering Broadcast Channels With Service Upgrade to Include Linear Streaming to Online Platforms

(UBIC) Brings in Top Executive Talent in North America

Joining the UBIC Executive team are David Ahrens, Chief Marketing Officer and Margaret Shaw Lilani as Senior Vice President, Review and Professional Services

SAN FRANCISCO, Jan. 13, 2016  — UBIC, Inc. (Nasdaq:UBIC) (TSE:2158), a leading provider of international litigation support and big-data analysis services, announced today that it has hired two key executives to help the company expand its operations in North America and also globally. Joining the UBIC executive team are David Ahrens in the role of Chief Marketing Officer, and Margaret Shaw Lilani as Senior Vice President, Review and Professional Services.

Photos accompanying this announcement are available at

As Chief Marketing Officer, Mr. Ahrens will be responsible for developing an integrated marketing and communications plan for the unified UBIC entity formed by the acquisition of Evolve and TechLaw, and rolling in UBIC North America into a centralized marketing function. This will include elements of lead generation, public relations, event management, a customer reference program, product and solution marketing, as well as digital marketing efforts. His vast experience in the software industry across marketing, business development and corporate strategy will provide valuable structure and processes to support the high growth objectives of the business. Previously, Mr. Ahrens was the CMO of Marsh ClearSight, and prior to that held senior management roles at both SAP and SAS.

Ms. Lilani joins as the Senior Vice President, Review and Professional Services and will be responsible for UBIC’s Review & Professional Services business globally. Ms. Lilani will focus on the integration of post-acquisition global service delivery and enhanced client experience through the application of advanced review workflows and best-of-breed technology. She will support international clients and law firms on cross border matters ensuring access to Tier 1 review facilities, people and technology and providing comprehensive solutions to the complex legal problems of UBIC’s clients. Additionally, she will work closely with UBIC’s Sales organization. Ms. Lilani is a trained attorney and has held previous executive roles at Epiq Systems and Kelly Services.

“As we continue our aggressive growth trajectory in the eDiscovery market, we enter 2016 unified, focused and ready to set the bar higher on client satisfaction”, says Andy F. Jimenez, Chief Executive Officer at UBIC North America. “We have great people here at UBIC today. And with David Ahrens joining our executive team, we have a proven leader who can bring our marketing and communications to another level in an articulate and resounding fashion. Margaret Lilani is an industry veteran who will deepen our leadership team, providing a clear path for clients to technology-enabled services that are faster and better than any in the industry.”

About UBIC, Inc.

UBIC, Inc. (Nasdaq:UBIC) (TSE:2158) supports the analysis of big data based on behavior informatics by utilizing its technology, “KIBIT”. UBIC’s KIBIT technology is driven by UBIC AI based on knowledge acquired through its litigation support services. The KIBIT incorporates experts’ tacit knowledge, including their experiences and intuitions, and utilizes that knowledge for big data analysis. UBIC continues to expand its business operations by applying KIBIT to new fields such as healthcare and marketing.

UBIC was founded in 2003 as a provider of e-discovery and international litigation support services. These services include the preservation, investigation and analysis of evidence materials contained in electronic data, and computer forensic investigation. UBIC provides e-discovery and litigation support by making full use of its data analysis platform, “Lit i View®”, and its Predictive Coding technology adapted to Asian languages.

For more information about UBIC, contact usinfo@ubicna.com or visit http://www.ubic-global.com.

Safe Harbor Statement

This announcement contains forward-looking statements. These forward-looking statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar statements. Among other things, the amount of data that UBIC expects to manage this year and the potential uses for UBIC’s new service in intellectual property-related litigation, contain forward-looking statements. UBIC may also make written or oral forward-looking statements in its reports filed with, or furnished to, the U.S. Securities and Exchange Commission, in its annual reports to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about UBIC’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: UBIC’s goals and strategies; UBIC’s expansion plans; the expected growth of the data center services market; expectations regarding demand for, and market acceptance of, UBIC’s services; UBIC’s expectations regarding keeping and strengthening its relationships with customers; UBIC’s plans to invest in research and development to enhance its solution and service offerings; and general economic and business conditions in the regions where UBIC provides solutions and services. Further information regarding these and other risks is included in UBIC’s reports filed with, or furnished to the Securities and Exchange Commission. UBIC does not undertake any obligation to update any forward-looking statement, except as required under applicable law. All information provided in this press release and in the attachments is as of the date of this press release, and UBIC undertakes no duty to update such information, except as required under applicable law.

CONTACT: 
UBIC Global PR
UBIC North America, Inc.
Tel: (212) 924-8242
global_pr@ubic.co.jp

(MCHP) Announces (ATML) Acquisition Proposal Deemed A “Superior Proposal” By BOD

CHANDLER, Ariz., Jan. 13, 2016  — Microchip Technology Incorporated (NASDAQ: MCHP), a leading provider of microcontroller, mixed-signal, analog and Flash-IP solutions today announced that it was informed last night that the Board of Directors of Atmel Corporation (NASDAQ: ATML) had determined that Microchip’s  proposal to acquire Atmel for $8.15 per share in a cash and stock transaction constitutes a “Superior Proposal” under the terms of Atmel’s merger agreement with Dialog Semiconductor PLC.

Under the terms of Microchip’s proposal, stockholders of Atmel will receive $7.00 per share in cash and $1.15 per share in Microchip common stock, valued at the average closing sale price for a share of Microchip common stock for the ten most recent trading days ending on the last trading day prior to the closing. The maximum number of Microchip shares to be issued in the transaction is 13.0 million, after which the cash consideration per share will be increased such that the combined cash and stock consideration will remain at $8.15 per share. Microchip was informed that Atmel has given written notice to Dialog of its intent to change its recommendation and terminate the Dialog transaction in favor of the Microchip proposal. As a result, Atmel will be entitled to terminate the Dialog merger agreement if Dialog does not make, within four business days following the receipt of the notice, a written, binding proposal that would cause the Microchip proposal to no longer constitute a “Superior Proposal.”

“The combined business of Microchip and Atmel will create a microcontroller, analog and internet of things (IoT) powerhouse. Atmel’s portfolio of microcontrollers, wireless, touch, memory and automotive products complements and enhances many of Microchip’s solutions in these areas.  We believe that combining Atmel’s business with Microchip’s business will offer our combined customers a broader range of innovative solutions to serve their needs, while creating significant long-term stockholder value,” said Steve Sanghi, President and CEO of Microchip.

“Microchip’s enduring vision is to be the very best embedded control solutions company ever. Our strategy behind this vision is to enable the growing market for smart, connected and secure solutions for the automotive, industrial, office automation, consumer and telecom markets. We believe that the combined microcontroller, analog, memory, automotive, security, computing, networking, wireless, touch, timing and technology licensing product lines of Microchip and Atmel will present a powerful portfolio of innovative solutions for these growing markets.  We also believe this acquisition will further enhance our analog and mixed-signal opportunities as we expect to attach these products to an expanded set of microcontroller customer applications,” said Ganesh Moorthy, COO of Microchip.

If Microchip and Atmel execute a merger agreement on the terms proposed by Microchip, the transaction is expected to be immediately accretive to Microchip’s non-GAAP earnings per share following the closing of such transaction.

J.P. Morgan is acting as Microchip’s exclusive financial advisor. Wilson Sonsini Goodrich & Rosati, P.C. is acting as Microchip’s legal advisor.

There will be no conference call held in connection with this press release.

About Microchip Technology

Microchip Technology Inc. (NASDAQ:  MCHP) is a leading provider of microcontroller, mixed-signal, analog and Flash-IP solutions, providing low-risk product development, lower total system cost and faster time to market for thousands of diverse customer applications worldwide.  Headquartered in Chandler, Arizona, Microchip offers outstanding technical support along with dependable delivery and quality.  For more information, visit the Microchip website at http://www.microchip.com.

Forward Looking Statements

The statements in this release relating to the combined business of Microchip and Atmel creating a microcontroller, analog and IoT powerhouse,  that Atmel’s portfolio of microcontrollers, wireless, touch, memory and automotive products complements and enhances many of Microchip’s solutions in these areas, our belief that combining Atmel’s business with Microchip’s business will offer our combined customers a broader range of innovative solutions to serve their needs, while creating significant long-term stockholder value, Microchip’s vision to be the very best embedded control solutions company ever, Microchip’s strategy to enable the growing market for smart, connected and secure solutions for the automotive, industrial, office automation, consumer and telecom markets, our belief that the combined microcontroller, analog, memory, automotive, security, computing, networking, wireless, touch, timing and technology licensing product lines of Microchip and Atmel will present a powerful portfolio of innovative solutions for these growing markets, our belief that this acquisition will further enhance our analog and mixed-signal opportunities as we expect to attach these products to an expanded set of microcontroller customer applications, and that the transaction is expected to be immediately accretive to Microchip’s non-GAAP earnings per share are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  These forward-looking statements are subject to a number of business, economic, legal and other risks that are inherently uncertain and difficult to predict, including, but not limited to: whether Microchip and Atmel actually enter into a merger agreement and the definitive terms of such agreement, the actual timing of the closing of the acquisition if the proposed merger agreement is executed,  the satisfaction of the conditions to closing in the proposed merger agreement (including obtaining Atmel stockholder approval and regulatory clearances), any termination of the existing merger agreement between Atmel and Dialog Semiconductor or the proposed merger agreement between Microchip and Atmel, changes in demand or market acceptance of the products of Atmel or Microchip and the products of their respective customers; competitive developments; the costs and outcome of any current or future litigation involving Microchip, Atmel or the acquisition transaction; the effect of the acquisition on Microchip’s and Atmel’s existing relationships with customers and vendors and their operating results and businesses; the progress and costs of development of Microchip and Atmel products and the timing and market acceptance of  those new products; Microchip’s ability to successfully integrate Atmel’s operations and employees, retain key employees and otherwise realize the expected synergies and benefits of the transaction; fluctuations in Microchip’s stock price which would impact the number of shares that Microchip issues in the transaction; and general economic, industry or political conditions in the United States or internationally.  For a detailed discussion of these and other risk factors, please refer to the SEC filings of Microchip and Atmel including those on Forms 10-K, 10-Q and 8-K.  You can obtain copies of Forms 10-K, 10-Q and 8-K and other relevant documents for free at Microchip’s website (www.microchip.com), at Atmel’s website (www.atmel.com) (as applicable) or the SEC’s website (www.sec.gov) or from commercial document retrieval services.

Stockholders of Microchip are cautioned not to place undue reliance on the forward-looking statements in this press release, which speak only as of the date such statements are made.  Microchip undertakes no obligation to publicly update any forward-looking statements to reflect events, circumstances or new information after this January 13, 2016 press release, or to reflect the occurrence of unanticipated events.

Additional Information and Where to Find It

If Microchip and Atmel execute a merger agreement on the proposed terms, Microchip will file a Registration Statement on Form S-4 that will include a proxy statement of Atmel in connection with the acquisition transaction.  Investors and security holders are urged to read this document when it becomes available because it will contain important information about the transaction. Investors and security holders may obtain free copies of these documents (when they are available) and other documents filed with the SEC at the SEC’s web site at www.sec.gov.  Microchip, Atmel and their directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Atmel in connection with the acquisition transaction.  Information regarding the special interests of these directors and executive officers in the transaction will be included in the proxy statement/prospectus described above.  Additional information regarding the directors and executive officers of Microchip is also included in Microchip’s proxy statement for its 2015 Annual Meeting of Stockholders, which was filed with the SEC on July10, 2015.  Additional information regarding the directors and executive officers of Atmel is also included in Atmel’s proxy statement for its 2015 Annual Meeting of Stockholders, which was filed with the SEC on April 3, 2015.  These documents are available free of charge at the SEC’s web site at www.sec.gov and as described above.

Note: The Microchip name and logo are registered trademarks of Microchip Technology Inc. in the USA and other countries.  All other trademarks mentioned herein are the property of their respective companies.

INVESTOR RELATIONS CONTACT:
J. Eric Bjornholt – CFO  (480) 792-7804

(WILN) Subsidiary Enters Into License Agreement With FEI

For media and investor inquiries, please contact:
Dave Mason
Investor Relations
LodeRock Advisors Inc.
613.688.1693
dave.mason@loderockadvisors.com

(CPAH) Achieves Cisco Compatibility Certification With the Cisco Solution Partner Program

Todd Carothers
Executive Vice President of Marketing and Products
e-mail: tcarothers@counterpath.com

(VHC) Court Issues New Order in (AAPL) Lawsuit

Ruling Covers Pending Motions Before Trial

ZEPHYR COVE, Nev., Jan. 12, 2016  — VirnetX™ Holding Corporation (NYSE MKT: VHC), an Internet security software and technology company, announced today that on January 11, 2016, in the Company’s pending litigation against Apple Inc., in the United States District Court for the Eastern District of Texas, Tyler Division, the court issued a comprehensive order with rulings on all of the pending Daubert and Dispositive motions, filed by both parties and pending before the court.

“We are pleased to have these extensive issues in the case resolved by the Court,” said Kendall Larsen, VirnetX CEO and President.  “We look forward to presenting our case to a jury on January 25^th, 2016.”

VirnetX has currently-pending patent infringement lawsuit, VirnetX Inc. v. Apple, Inc. (Case 6:12-CV-00855-LED), in United States Court for the Eastern District of Texas, Tyler Division. This Civil Action includes the remanded portions of the Civil Action Case 6:10-CV-00417-LED (VirnetX vs. Cisco et. al.). The jury selection and trial in this Civil Action is scheduled to start on January 25, 2016.

About VirnetX

VirnetX Holding Corporation is an Internet security software and technology company with patented technology for secure communications including 4G LTE security. The Company’s software and technology solutions, including its secure domain name registry and Gabriel Connection Technology™, are designed to facilitate secure communications and to create a secure environment for real-time communication applications such as instant messaging, VoIP, smart phones, eReaders and video conferencing. The Company’s patent portfolio includes over 112 U.S. and international patents and over 75 pending applications. For more information, please visit www.virnetx.com

Forward Looking Statements

Statements in this press release that are not statements of historical or current fact, including statements regarding the  strength of VirnetX’s intellectual property, constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.  Such forward-looking statements are based on expectations, estimates and projections about the markets in which the Company operates, management’s beliefs, and certain assumptions made by management and involve known and unknown risks, uncertainties and other unknown factors that could cause the actual results of the Company to be materially different from the historical results or from any future results expressed or implied by such forward-looking statements, including but not limited to (1) the outcome of any legal proceedings that have been or may be initiated by the Company or that may be initiated against the Company, including pending and future inter partes review proceedings in the Patent and Trademark Office; (2) the ability to capitalize on the Company’s patent portfolio and generate licensing fees and revenues; (3) the ability of the Company to be successful in entering into licensing relationships with its targeted customers on commercially acceptable terms; (4) potential challenges to the validity of the Company’s patents underlying its licensing opportunities; (5) the ability of the Company to achieve widespread customer adoption of the Company’s Gabriel Communication Technology™ and its secure domain name registry; (6) the level of adoption of the 3GPP Series 33 security specifications; (7) whether or not the Company’s patents or patent applications may be determined to be or become essential to any standards or specifications in the 3GPP LTE, SAE project or otherwise; (8) the extent to which specifications relating to any of the Company’s patents or patent applications may be adopted as a final standard, if at all; and (9) the possibility that Company may be adversely affected by other economic, business, and/or competitive factors.  In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” or “plans” to be uncertain and forward-looking.  The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s reports and registration statements filed with the Securities and Exchange Commission, including those under the heading “Risk Factors” in Company’s Quarterly Report on Form 10-Q filed with the SEC on November 9, 2015.  Many of the factors that will determine the outcome of the subject matter of this press release are beyond the Company’s ability to control or predict.  Except as required by law, the Company is under no duty to update any of the forward-looking statements after the date of this press release to conform to actual results.

Contact:
Investor Relations
VirnetX Holding Corporation
775.548.1785
ir@virnetx.com

VirnetX, Gabriel Collaboration Suite, Gabriel Secure Communications Platform and GABRIEL Connection Technology are trademarks of VirnetX Holding Corporation. Other company and product names may be trademarks of their respective owners.

(RCON) Signs Agreement with PetroChina’s Qinghai Oilfield

BEIJING, Jan. 12, 2016  — Recon Technology, Ltd. (NASDAQ: RCON) (“Recon” or the “Company”), a leading independent oilfield services provider operating primarily in China, announced today that Beijing BHD Petroleum Technology Co., Ltd. (“BHD”), a subsidiary of the Company, has executed an agreement (the “Agreement”) with Qinghai Oilfield, a PetroChina Co., Ltd. (“PetroChina”) subsidiary, to sell chemical agents (the “Chemicals”) to Qinghai Oilfield. The Chemicals, including Ion Modifiers and Water Quality Stabilizers, are designed and tested by BHD and are to be used for wastewater treatment at the Qinghai Oilfield. This Agreement, which is valued at RMB 3.98 million (~$0.6 million), is expected to be completed by the end of FY2016.

This Agreement follows BHD’s recent win of a major bidding contract with PetroChina that qualified BHD as a Class A Furnace Supplier to all of PetroChina’s oilfield companies and a RMB 3.2 million (~$0.5 million) contract to supply five furnaces to PetroChina’s Huabei Oilfield.

“We continue to grow our presence at PetroChina’s oilfield companies,” said Mr. Shenping Yin, Chairman and Chief Executive Officer. “Today’s announcement follows months of efforts by our BHD team and marks another breakthrough for us with PetroChina as we seek opportunities to expand our product and service offerings. The oilfield waste water treatment segment is a brand new market for Recon. Aside from the chemicals, we expect to provide more professional waste water treatment equipment to our oilfield client in the coming year, which we are in the process of developing now. We are optimistic that this consignment sale of third party chemicals has the potential to evolve into a new line of business on a recurring basis for Recon.”

About Recon Technology, Ltd.

Recon Technology, Ltd. (NASDAQ: RCON) (“Recon”) is China’s first independent oil and gas field service company to be listed on NASDAQ. Working closely with leading global partners, Recon has achieved rapid growth supplying China’s largest oil and gas exploration companies, including Sinopec and China National Petroleum Corporation, with advanced automated technologies, efficient gathering and transportation equipment and reservoir stimulation measures. The solutions Recon provides are aimed at increasing gas and petroleum extraction levels, reducing impurities, improving safety and lowering production costs. For additional information, please visit www.recon.cn.

Cautionary Statements

Statements made in this release with respect to Recon’s current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Recon. Forward-looking statements include, but are not limited to, those statements using words such as “believe,” “expect,” “plans,” “strategy,” “prospects,” “forecast,” “estimate,” “project,” “anticipate,” “aim,” “intend,” “seek,” “may,” “might,” “could” or “should,” and words of similar meaning in connection with a discussion of future operations, financial performance, events or conditions. From time to time, oral or written forward-looking statements may also be included in other materials released to the public. These statements are based on management’s assumptions, judgments and beliefs in light of the information currently available to it. Recon cautions investors that a number of important risks and uncertainties could cause actual results to differ materially from those discussed in the forward-looking statements, including but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in reports filed by the company with the Securities and Exchange Commission. Therefore investors should not place undue reliance on such forward-looking statements. Actual results may differ significantly from those set forth in the forward-looking statements. 

All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

Contact:

Recon Technology, Ltd.
Jia Liu, Chief Financial Officer
Tel: +86-10-8494-5799
Email: info@recon.cn

Weitian Investor Relations
Tina Xiao
Tel: +1-917-609-0333
Email: tina.xiao@weitian-ir.com

(SGI) Appoints Nina Richardson to Board of Directors

(MOXC) Covered by Crystal Equity Research

(FUEL) a Visionary in Gartner’s 2016 Magic Quadrant for Digital Marketing Hubs

Rocket Fuel (NASDAQ: FUEL), a leading Programmatic Marketing Platform provider, today announced that it has been positioned by Gartner, Inc. in the “Visionaries” quadrant of the “Magic Quadrant for Digital Marketing Hubs” report for the second consecutive year.¹

“The recognition by Gartner as a visionary affirms our advancements in delivering on the marketer’s vision of finding and interacting with customers at the precise moment of influence to improve performance across both owned and paid channels,” said Simon Hayhurst, Rocket Fuel senior vice president of products. “Moment Scoring is at the core of our programmatic marketing platform’s strength in activating a wealth of data across both channels, allowing our clients to deliver moment-based marketing campaigns which improve their return on ad spend and deliver new levels of insight.”

Rocket Fuel’s Programmatic Marketing Platform

The Gartner report recognized Rocket Fuel as a visionary for its Programmatic Marketing Platform, which offers superior service and support for both a Data Management Platform (DMP) and a Demand Side Platform (DSP) to help marketers and their agencies help marketers centralize and activate data from every channel, including display, mobile, video, offline CRM data, website, and email marketing. Rocket Fuel’s unique Moment Scoring™ technology, which underpins its Programmatic Marketing Platform, is designed to learn the critical predictors of what makes one marketing action more likely than another in a particular moment, and, in real time, improves campaigns accordingly.

Additional information on Rocket Fuel’s recognition as a Visionary in the Gartner Magic Quadrant for Digital Marketing Hubs can be found here: http://rocketfuel.com/rocket-fuel-named-visionary-by-gartner.

Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

[1]Gartner, Magic Quadrant for Digital Marketing Hubs by Andrew Frank, Jake Sorofman, Martin Kihn, Christi Eubanks, January 5, 2016

About Rocket Fuel

A leading Programmatic Marketing Platform provider, Rocket Fuel (NASDAQ: FUEL) offers brands, agencies, and platform partners managed services, as well as a SaaS-based Data Management Platform (DMP) and Demand Side Platform (DSP), to optimize performance, awareness, and lift across marketing objectives, channels and devices. By applying artificial intelligence at big data scale, Rocket Fuel’s Moment Scoring™ technology performs a real-time calculation of each ad opportunity based on a marketer’s goal to determine the likelihood a consumer will engage in a desired action. Moment Scoring goes beyond 1:1 marketing by learning to predict what marketing actions to take with a campaign at a precise moment in time, which results in a much more efficient use of marketing dollars. Rocket Fuel serves 96 of the Ad Age 100, three of the top five agency holding company trading desks, and partners with some of the world’s leading CRM platforms, marketing platforms and systems integrators. Headquartered in Redwood City, California, Rocket Fuel has more than 20 offices worldwide.

Media Contact:
Rocket Fuel
Kristin Holloway, 650-481-6178
pr@rocketfuel.com

(CETX) CEO, Saagar Govil, Makes Forbes’ 30 Under 30 List

FARMINGDALE, N.Y., Jan. 11, 2016  — Cemtrex (NASDAQ: CETX), a diversified industrial and manufacturing leader, announced today that its Chairman and CEO was recently selected by Forbes as one of its “30 Under 30.” The list represents Forbes’ selection of the brightest young entrepreneurs, breakout talents, and change agents in 20 different sectors.

Forbes initially screened over 15,000 candidates representing the best of the best, to ultimately reach their stringent selection of outstanding individuals who were recognized under the 2016 30 Under 30. According to Caroline Howard of the publication, “In the past, youth was a handicap to professional success. Getting older meant more resources, more knowledge, more money. No more. Those who grew up in the tech age have way bigger ambitions — perfectly suited to the dynamic, entrepreneurial and impatient digital world they grew up in. If you want to change the world, being under 30 is now an advantage.”

Some names on this year’s list include recognizable names: NBA champ Stephen Curry, Star Wars: The Force Awakens leading man John Boyega, plus-sized supermodel Ashley Graham, Canadian crooner Shawn Mendes and YouTube gamer CaptainSparklez (Jordan Maron). Notable 30 Under 30 Alumni from previous years include influential people like Adele and Mark Zuckerberg.

Cemtrex’s CEO, Saagar Govil, commented, “I am honored and humbled to be recognized and associated with such an elite group of successful and innovative individuals. The people on this list have accomplished a tremendous amount in their brief careers and some of the alumni from past years are global leaders in their industries now only a few years later. Cemtrex has achieved strong success the last few years, being one of the fast growing industrial companies over the last 5 years in terms of revenue. Our goal is to continue that trend upward and keep building toward greater heights.”

About Cemtrex

Cemtrex, Inc. (NASDAQ:CETX) is a world leading diversified industrial and manufacturing company that provides a wide array of solutions to meet today’s technology challenges. Cemtrex provides manufacturing services of advanced custom engineered electronics, industrial services, monitoring instruments for industrial processes and environmental compliance, and systems for controlling particulates, hazardous gases, emissions of Greenhouse gases, and other regulated pollutants used in emissions trading globally.

www.cemtrex.com

Safe Harbor Statement
This press release contains forward-looking statements. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date.

For further information, please contact:

Investor Relations
Cemtrex, Inc.
Phone: 631-756-9116
Email

(KONA) Announces Preliminary Fourth Quarter 2015 Restaurant Sales

Same-Store Sales Increase 3.2%

SCOTTSDALE, Ariz., Jan. 11, 2016  — Kona Grill, Inc. (NASDAQ:KONA), an American grill and sushi bar, today announced preliminary restaurant sales for the quarter ended December 31, 2015. Restaurant sales increased 20.6% to $38.1 million, compared to $31.6 million for the same quarter last year. Same-store sales increased 3.2% compared to an increase of 3.1% in the fourth quarter of 2014.

For fiscal year 2015, restaurant sales increased 20.1% to $143.0 million, compared to $119.1 million for fiscal year 2014.  The increase was driven by sales associated with the opening of seven restaurants during 2015, four of which were opened in the fourth quarter, incremental sales from five restaurants opened during 2014 and same-store sales growth of 2.0%.

Berke Bakay, President and CEO of Kona Grill, commented, “We are pleased to drive 3.2% same-store sales growth during the fourth quarter, especially given recent trends in the industry. With positive same-store sales growth in 21 of the last 22 quarters, we continue to take market share with our innovative food and drink offerings and contemporary design. Our strong sales momentum, track record of execution and a robust development pipeline make us uniquely positioned as one of the fastest growing and exciting restaurant concepts in the country.”

International Development Update

The Company recently signed a non-binding letter of intent for the development of Kona Grill restaurants in Mexico.  This letter of intent is in addition to a non-binding letter of intent for development in the Middle East.

ICR Conference

The Company will be presenting at the 18^th Annual ICR Conference at the JW Marriott Orlando Grande Lakes in Orlando, FL on Tuesday, January 12, 2016.  Berke Bakay, President and CEO, and Christi Hing, CFO, are hosting the presentation, which will begin at 10:00 am Eastern Time.  Investors and interested parties may view the investor presentation by visiting the investor relations section within the Company’s website at www.konagrill.com.

About Kona Grill

Kona Grill (NASDAQ:KONA) features a global menu of contemporary American favorites, award-winning sushi, and specialty cocktails. Kona Grill owns and operates 37 restaurants, guided by a passion for quality food and personal service. Restaurants are currently located in 19 states and Puerto Rico: Arizona (Chandler, Gilbert, Phoenix, Scottsdale); Colorado (Denver); Connecticut (Stamford); Florida (Miami, Sarasota, Tampa); Georgia (Alpharetta); Idaho (Boise); Illinois (Lincolnshire, Oak Brook); Indiana (Carmel); Louisiana (Baton Rouge); Maryland (Baltimore); Michigan (Troy); Minnesota (Eden Prairie); Missouri (Kansas City); Nebraska (Omaha); New Jersey (Woodbridge); Nevada (Las Vegas(2)); Ohio (Cincinnati, Columbus); Puerto Rico (San Juan); Texas (Austin, Dallas, El Paso, Fort Worth, Friendswood, Houston, Plano, San Antonio, The Woodlands); Virginia (Arlington, Richmond). For more information, visit www.konagrill.com.

Forward-Looking Statements

The Company reminds investors these sales figures are preliminary estimates and could differ from final audited fourth quarter and full year results. Various remarks we make about future expectations, plans, and prospects for the company constitute forward-looking statements for purposes of the Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding our expectations, beliefs, intentions, plans, objectives, goals, strategies, future events, or performance and underlying assumptions and other statements that are not purely historical. These statements relate to our future financial performance and growth goals for 2016 and beyond. We have attempted to identify these statements by using forward-looking terminology such as “may,” “will,” “anticipates,” “expects,” “believes,” “intends,” “should,” or comparable terms. All forward-looking statements included in this press release are based on information available to us on the date of this release and we assume no obligation to update these forward-looking statements for any reason. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those described in the statements. Investors are referred to the full discussion of risks and uncertainties associated with forward-looking statements and the discussion of risk factors contained in the company’s filings with the Securities and Exchange Commission.

Kona Grill Investor Relations Contact:
Kona Grill, Inc.
Christi Hing, Chief Financial Officer
(480) 922-8100
investorrelations@konagrill.com

(APOL) Explores Strategic Alternatives

Apollo Education Group, Inc. (Nasdaq: APOL) announced today that the Board of Directors has made the determination to explore strategic alternatives while the Company continues to execute its ongoing business transformation. The Board is currently in discussions that could potentially lead to a change of control of the Company. The Board believes that these actions will support and accelerate Apollo’s strategic initiatives, which include the continued growth and investment in Apollo Global and the continuation of the University of Phoenix’s transformation plan to further enhance student outcomes and provide outstanding, career relevant higher education for working adults.

The Company has retained Barclays and Credit Suisse as financial advisors and Sullivan & Cromwell as legal advisor. There can be no assurance that any transaction will be pursued or completed. Given the ongoing nature of these discussions, the Company will not make any further comment at this time.

About Apollo Education Group, Inc
Apollo Education Group, Inc. is one of the world’s largest private education providers, serving students since 1973. Through its subsidiaries, Apollo Education Group offers undergraduate, graduate, professional development and other nondegree educational programs and services, online and on-campus principally to working learners. Its educational programs and services are offered throughout the United States and in Europe, Australia, Latin America, Africa and Asia, as well as online throughout the world. For more information about Apollo Education Group, Inc. and its subsidiaries, call (800) 990-APOL or visit the Company’s website at www.apollo.edu.

Forward-Looking Statements Safe Harbor
Statements about Apollo Education Group and its business in this release which are not statements of historical fact, including statements regarding Apollo Education Group’s future strategy and plans and commentary regarding future results of operations and prospects, are forward-looking statements and are subject to the Safe Harbor provisions created by the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current information and expectations and involve a number of risks and uncertainties. Actual plans implemented and actual results achieved may differ materially from those set forth in or implied by such statements due to various factors, including without limitation: (i) the impact of increased competition from traditional public universities and proprietary educational institutions; (ii) the impact of the initiatives to transform University of Phoenix into a more focused, higher retaining and less complex institution, including the near-term impact on enrollment; (iii) the impact of the Company’s ongoing restructuring and cost-reduction initiatives; (iv) impacts from actions taken by our regulators that could affect University of Phoenix’s eligibility to participate in or the manner in which it participates in U.S. federal and state student financial aid programs; (v) further delay in the University’s pending recertification by the U.S. Department of Education for participation in Title IV student financial aid programs, or any limitations or qualifications imposed in connection with any recertification; (vi) the impact of the U.S. Department of Defense (“DoD”) action to place University of Phoenix on probation in relation to participation in the DoD’s Tuition Assistance Program for active duty military students; (vii) the impact of any reduction in financial aid available to students, including active and retired military personnel, due to the U.S. government deficit reduction proposals, debt ceiling limitations, budget sequestration or otherwise; (viii) changes in University of Phoenix enrollment or student mix; and (ix) unexpected expenses or other challenges in integrating acquired businesses, consumer or regulatory impact arising from consummation of such acquisitions, and unexpected changes or developments in the acquired businesses. For a discussion of the various factors that may cause actual plans implemented and actual results achieved to differ materially from those set forth in the forward-looking statements, please refer to the risk factors and other disclosures contained in Apollo Education Group’s Form 10-K for fiscal year 2015, most recently filed 10-Q, and other filings with the Securities and Exchange Commission which are available at www.apollo.edu.

Brunswick Group
Tripp Kyle / Tom Maginnis
(212) 333 3810
apollo@brunswickgroup.com

(ANY) Collab. w/ (MSFT) to Bring SnapCLOUD Adopters to Azure Marketplace

Simple and expandable storage platform to provision enterprise cloud storage proves a winning combination in Microsoft Marketplace

San Jose, California–(January 11, 2016) – Sphere 3D Corp. (NASDAQ: ANY), a containerization, virtualization and data management solutions provider and parent company of Overland Storage and Tandberg Data, today announced encouraging initial results from its Microsoft Azure joint marketing campaign. In-market tactics launched in late November 2015 were directed to a control portion, subset of its dedicated customers that use its SnapServer® and SnapScale® on-premise storage solutions. The campaign entices them to augment their existing solutions with Sphere 3D’s SnapCLOUD™ – a cloud-based data storage product which is available from the Microsoft Azure Marketplace. The campaign has already resulted in over 100 SnapCLOUD customer deployments, meeting 40% of the target goal for the original 90-day period.

“This effort is designed to galvanize the inter-relationships of the various brands within the Sphere3D portfolio. We believe we will continue to gain traction through vertical integration of our distinctive capabilities that are designed to catalyze adoption of our products,” said Eric Kelly, CEO of Sphere 3D. “Many of these same loyal SnapServer and SnapScale customers have also begun looking at our G-Series Cloud, application containerization solution, powered by Glassware 2.0™, which is also available in the Microsoft Azure Marketplace.”

“My organization has been very pleased with the SnapServer product line and I view it as a trusted brand for reliability, data protection, and enterprise-grade performance,” said Macon Barham, owner of a leading national insurance agency, based in Peachtree City, GA. “When we learned about the SnapCLOUD solution last month, with its ability to provision our unstructured data in minutes within the Microsoft Azure Cloud Marketplace, it was an easy decision to help round out our data storage infrastructure.” He continued by stating, “I really like how the cloud approach allows me to control expenses by paying only for what we use; and if we need more we can quickly increase our capacity without taking on the IT expense or burden of build out and technical support.”

Sphere 3D has a large customer base of SnapServer users, consisting of both Small and Medium-sized Business (SMBs), as well as large enterprises, that are seeking to augment their on-premise storage solutions with a hybrid cloud infrastructure. The SnapCLOUD offering in the Microsoft Azure Marketplace allows customers to easily deploy a cloud-based solution while recognizing the great benefits of flexibility, load balancing and security offered by Microsoft Azure.

For a trial of SnapCLOUD from Microsoft Azure, go to https://azure.microsoft.com/en-us/marketplace/partners/sphere3d/snapcloud-standard/.

About SnapCLOUD

SnapCLOUD™ is a virtual storage platform based on Sphere 3D’s SnapServer® on-premise data storage operating system, which has been installed by 300,000 plus customers worldwide. SnapCLOUD brings the simplicity of deploying enterprise-grade data storage in minutes to meet unplanned business growth needs. The storage offering is unique in its ability to unify data manageability, access control and replication between the physical data center and the public cloud, because it is a true hybrid cloud architecture. SnapCLOUD delivers the following benefits:

• Users can create a high performance and resilient virtual environment in minutes, using servers, storage and networking from the Microsoft Azure Marketplace. On top of this, customers only pay for what they use.
• Users get secure data access anywhere and on any device. Built-in sync and share functionality enables users and devices to share data directly from SnapCLOUD in conformance with business policies.
• Users can centrally manage and monitor their on-premise physical data center and their data in the cloud, allowing data management across the organization to be the same everywhere.

About Sphere 3D

Sphere 3D Corp. (NASDAQ: ANY) delivers containerization and virtualization technologies along with data management products that enable workload-optimized solutions. We achieve this through a combination of containerized applications, virtual desktops, virtual storage and physical hyper-converged platforms. Sphere 3D’s value proposition is simple and direct—we allow organizations to deploy a combination of public, private or hybrid cloud strategies while backing them up with state of the art storage solutions. Sphere 3D, along with its wholly-owned subsidiariesOverland Storage andTandberg Data, has a strong portfolio of brands includingGlassware 2.0™,SnapCLOUD™, SnapScale®, SnapServer®,V3, RDX®, and NEO®. For more information, visit www.sphere3d.com.

# # #

Media Contacts:
Eileen Elam
408-283-4734
media.relations@sphere3d.com

Nick Foot
BWW Communications
+44-1491-636393
Nick.foot@bwwcomms.com

Investor Contact:
Blueshirt Group
Michael Bishop
415-217-4968
mike@blueshirtgroup.com

Safe Harbor Statement

This press release may contain forward-looking statements that involve risks, uncertainties, and assumptions that are difficult to predict. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of risks and uncertainties including, without limitation, unforeseen changes in the course of Sphere 3D’s business or the business of its wholly-owned subsidiaries, including, without limitation, Overland Storage and Tandberg Data;; the level of success of our collaborations and business partnerships; possible actions by customers, partners, suppliers, competitors or regulatory authorities; and other risks detailed from time to time in Sphere 3D’s periodic reports contained in our Annual Information Form and other filings with Canadian securities regulators (www.sedar.com) and in prior periodic reports filed with the United States Securities and Exchange Commission (www.sec.gov). Sphere 3D undertakes no obligation to update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.

(MYL) Announces Worldwide Collaboration with (MNTA)

Partnership Builds on Successful Existing Collaboration with Biocon and Positions Mylan as a World Leader in Biosimilars

HERTFORDSHIRE, England and PITTSBURGH, Jan. 8, 2016  — Mylan N.V. (NASDAQ, TASE: MYL) today announced that it has entered into an exclusive global collaboration agreement with Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) to develop, manufacture and commercialize six of Momenta’s current biosimilar candidates, including Momenta’s biosimilar candidate, ORENCIA® (abatacept).

Mylan CEO Heather Bresch commented, “Mylan’s long-stated strategy has been to strategically invest in the long-term drivers of our future growth, both through our strong internal focus on R&D and through external collaboration with industry-leading partners. Biosimilars have long been one of these areas of important future growth, both for our company and our industry, given the rapidly growing market for biologic products, the undeniable patient need for more affordable versions of these life-saving medicines, and the attractive competitive landscape for the companies that are able to successfully bring these complex products at scale to the global market. This collaboration with Momenta, which is highly complementary to our partnership with Biocon, will position us as a definitive world leader in biosimilars, with a broad portfolio of 15 biosimilar/insulin analog generic products in development and the scale required to maximize investment in this area. Looking forward, Mylan will continue to expand and diversify its portfolio into such complex products, further differentiating us from other leading generics companies and establishing us at the forefront of the biologics space, while also ensuring we maintain one of the broadest, highest quality portfolios in our industry.”

“This exciting collaboration with Momenta is focused on the next wave of biosimilar products and represents an important next step for Mylan, leveraging Momenta’s unique technology capabilities and Mylan’s strong science, biosimilar-development experience, operational excellence and expansive global commercial footprint. Importantly, this collaboration builds upon Mylan’s existing successful biologics and insulins collaboration with Biocon, which is focused on more near-term biosimilar opportunities. Through these partnerships, as well as the strong internal capabilities we have cultivated, Mylan is further expanding what is already one of the industry’s most robust and diverse biosimilar portfolios and helping to ensure we can deliver enhanced access to these critical products to patients around the world,” continued Ms. Bresch.

Craig A. Wheeler, president and chief executive officer of Momenta Pharmaceuticals, said, “We are thrilled to welcome Mylan as our new collaboration partner for biosimilars. Our two companies have a common focus on building an industry-leading biosimilar portfolio that offers safe, effective and affordable products to the patients that need them. By combining Momenta’s proven capabilities in complex-product development and Mylan’s world-class global R&D, supply chain and commercial infrastructure, we are well positioned to become a strong competitor in this developing field. Our joint vision is to bring high quality, cost-effective biosimilar products to markets worldwide, and we believe our success will deliver a strong return to our companies’ stakeholders.”

Under the agreement with Momenta, Mylan will make an up-front cash payment of $45 million and up to $200 million in contingent milestone-related payments to Momenta, with each company sharing equally in the costs and profits with respect to the products. The companies will be jointly responsible for product development, and Mylan will lead worldwide commercialization efforts. All other financial terms and product details remain confidential.

Mylan’s collaboration with Momenta builds upon Mylan’s existing biologics and insulin analog partnership with Biocon. The Biocon partnership includes six biosimilar programs (trastuzumab, pegfilgrastim, adalimumab, bevacizumab, etanercept and filgrastim) and three insulin analogs (glargine, lispro and aspart). Five of these biosimilar programs have successfully completed Phase I clinical trials, and four of the programs are in active Phase III testing. Mylan and Biocon plan on submitting three biosimilar applications and one insulin application in the U.S. and Europe in 2016. Mylan already has successfully launched its trastuzumab biosimilar product in India and other emerging markets.

Mylan President Rajiv Malik commented, “Mylan has been fully engaged in the development of biosimilars with our partner Biocon for the last six years. During that time, Mylan has cultivated strong experience and expertise in the development of biosimilar products, and is executing on our programs with the scientific and analytical rigor required to fulfill health-authority expectations. Based upon our proactive and informative interactions with global health authorities on our nine active programs, we are extremely optimistic about the strength of our current development programs with Biocon, and we look forward to deploying our expertise in our collaboration with Momenta.”

Momenta also is providing information regarding the collaboration on its website.

Forward Looking Statement for Mylan

This press release includes statements that constitute “forward-looking statements,” including with regard to statements that biosimilars has long been an area of important future growth, both for Mylan and its industry, given the rapidly growing market for biologic products, the undeniable patient need for more affordable versions of these medicines, and the attractive competitive landscape for the companies that are able to successfully bring these complex products at scale to the global market; that the collaboration with Momenta, which is highly complementary to Mylan’s partnership with Biocon, will position Mylan as a definitive world leader in biosimilars with a broad portfolio of 15 biosimilar/insulin analog generic products in development and the scale required to maximize investment in this area; that Mylan will continue to expand and diversify its portfolio into such complex products, further differentiating it from other leading generics companies and establishing us at the forefront of the biologics space, while also ensuring it maintains one of the broadest, highest quality portfolios in its industry; that the collaboration with Momenta is focused on the next wave of biosimilar products and represents an important next step for Mylan, leveraging Momenta’s unique technology capabilities and Mylan’s strong science, biosimilar development experience, operational excellence and expansive global commercial footprint; that through Mylan’s partnerships, as well as the strong internal capabilities it has cultivated, Mylan is further expanding what is already one of the industry’s most robust and diverse biosimilar portfolios and helping to ensure we can deliver enhanced access to these critical products to patients around the world; that Mylan and Momenta have a common focus on building an industry leading biosimilar portfolio that offers safe, effective and affordable products to the patients that need them; that Mylan and Momenta’s joint vision is to bring high quality, cost effective biosimilar products to markets worldwide and they believe their success will deliver a strong return to their respective stakeholders; that Mylan and Biocon plan on submitting three biosimilar applications and one insulin application in the U.S. and Europe in 2016; that Mylan is executing on its programs with the scientific and analytical rigor required to fulfill health authority expectations; and that Mylan is extremely optimistic about the strength of its current development programs with Biocon and looks forward to deploying its expertise in our collaboration with Momenta.  These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: any changes in or difficulties with Mylan’s or its partners’ ability to develop, manufacture, and commercialize biosimilar candidates; any regulatory, legal, or other impediments to Mylan’s or its partners’ ability to bring biosimilar candidates to market; Mylan’s and its partners’ ability to protect intellectual property and preserve intellectual property rights, including with respect to biosimilar candidates; the effect of any changes in Mylan’s or its partners’ customer and supplier relationships and customer purchasing patterns; other changes in third-party relationships; the impact of competition; changes in the economic and financial conditions of the businesses of Mylan or its partners; the scope, timing, and outcome of any ongoing legal proceedings and the impact of any such proceedings on Mylan’s or its partners’ business; actions and decisions of healthcare and pharmaceutical regulators, and changes in healthcare and pharmaceutical laws and regulations, in the United States and abroad; risks associated with international operations; clearance under the Hart-Scott-Rodino Antitrust Improvements Act; other uncertainties and matters beyond the control of management; and the other risks detailed in Mylan’s filings with the Securities and Exchange Commission. Mylan undertakes no obligation to update these statements for revisions or changes after the date of this release.

Forward Looking Statement for Momenta Pharmaceuticals

Statements in this press release regarding management’s future expectations, beliefs, intentions, goals, strategies, plans or prospects, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements about our and Mylan’s ability to successfully develop and commercialize high quality, cost-effective biosimilar products; compete successfully in biosimilars; and increase shareholder value.  Such forward-looking statements involve known and unknown risks, uncertainties and other factors, including receiving clearance under the Hart-Scott-Rodino Antitrust Improvements Act and those referred to under the section “Risk Factors” in Momenta’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2015 filed with the Securities and Exchange Commission, as well as other documents that may be filed by Momenta from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, or the risks and factors noted above by Mylan, Momenta’s actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. Momenta is providing information in this press release as of this date and assumes no obligations to update the information or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

About Mylan

Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what’s right, not what’s easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,400 generic and branded pharmaceuticals, including antiretroviral therapies on which nearly 50% of people being treated for HIV/AIDS in the developing world depend. We market our products in approximately 165 countries and territories. Our global R&D and manufacturing platform includes more than 50 facilities, and we are one of the world’s largest producers of active pharmaceutical ingredients. Every member of our more than 30,000-strong workforce is dedicated to creating better health for a better world, one person at a time. Learn more at mylan.com.

(EXFO) to Present at Needham Growth Conference

QUEBEC CITY, Jan. 8, 2016  – EXFO Inc. (NASDAQ: EXFO, TSX: EXF) announced today that Germain Lamonde, Chairman, President and CEO, will make a presentation on behalf of the company at the annual Needham Growth Conference on January 12, 2016, 12:50 p.m. Eastern time, in New York.

Mr. Lamonde will outline EXFO’s investment proposition, market opportunities and competitive advantages to institutional investors on-site.

An audio Webcast of the presentation will be available live at www.EXFO.com, under the Investors section. It will also be archived for a limited period.

IR Calendar

• Annual Needham Growth Conference, January 12, 2016, 12:50 p.m. Eastern time, New York (Audio Webcast: www.EXFO.com/investors).

About EXFO
EXFO enables extraordinary experiences over global networks. Our test, service assurance and network visibility solutions allow network operators and equipment manufacturers to deliver a wealth of services to consumers, while increasing network capacity and reducing operating costs. From a company executive holding a telepresence meeting with overseas staff to a runner transferring data from wearable technology, EXFO’s inherent expertise and powerful analytics render these events commonplace. Simply put, we have evolved over our 30-year history to ensure unmatched quality of service and quality of experience on next-generation fixed and mobile networks. EXFO has a staff of approximately 1500 people in 25 countries, supporting more than 2000 customers worldwide. For more information, visit www.EXFO.com and follow us on the EXFO Blog, Twitter, LinkedIn, Facebook, Google+ and YouTube.

(CYBE) Announces $2.0 Million Follow-On Order for 3D AOI Systems

CyberOptics Corporation (Nasdaq: CYBE) today announced an order valued at approximately $2.0 million for SQ3000 automated optical inspection (AOI) systems, based upon the company’s 3D MRS inspection technology platform. Scheduled for shipment in the first quarter of 2016, this order follows a previously reported $750,000 order for SQ3000 systems that shipped in the fourth quarter of 2015.

Subodh Kulkarni, president and chief executive officer, said: “As evidenced by these recent sizeable orders, our differentiated 3D MRS technology is enabling CyberOptics to gain share in the global AOI market. This order activity reaffirms our confidence in CyberOptics’ future.”

About CyberOptics
CyberOptics Corporation (www.cyberoptics.com) is a leading global developer and manufacturer of high precision sensing technology solutions. CyberOptics’ sensors are used in general purpose metrology and 3D scanning, surface mount technology (SMT) and semiconductor markets to significantly improve yields and productivity. By leveraging its leading edge technologies, the company has strategically established itself as a global leader in high precision 3D sensors, allowing CyberOptics to further increase its penetration of key vertical markets. Headquartered in Minneapolis, Minnesota, CyberOptics conducts worldwide operations through its facilities in North America, Asia and Europe.

Statements regarding the Company’s anticipated performance are forward-looking and therefore involve risks and uncertainties, including but not limited to: market conditions in the global SMT and semiconductor capital equipment industries; increasing price competition and price pressure on our product sales, particularly our SMT systems; the level of orders from our OEM customers; the availability of parts required to meet customer orders; unanticipated product development challenges; the effect of world events on our sales, the majority of which are from foreign customers; rapid changes in technology in the electronics markets; product introductions and pricing by our competitors; the success of our 3D technology initiatives; expectations regarding LDI and its impact on our operations; integration risks associated with LDI and other factors set forth in the Company’s filings with the Securities and Exchange Commission.

(GLUU) Announces Date of Fourth Quarter and Full Year 2015 Financial Results

Glu Mobile Inc. (NASDAQ:GLUU), a leading global developer and publisher of free-to-play games for smartphone and tablet devices, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2015 after the U.S. markets close on Wednesday, February 3, 2016.

In conjunction with this announcement, Glu will host a conference call on February 3, 2016 at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) to discuss the company’s financial results. To access this call, dial (866) 582-8907 (domestic), or (760) 298-5046 (international), with conference ID #22306718. A replay of this conference call will be available between 4:30 p.m. PT February 3, 2016 and 8:59 p.m. PT, February 10, 2016 by calling (855) 859-2056, or (404) 537-3406, with conference ID #22306718. A live webcast of this conference call will also be available on the investor relations portion of the company’s website at www.glu.com, and a replay will be archived on the website as well.

About Glu Mobile

Glu Mobile (NASDAQ:GLUU) is a leading global developer and publisher of free-to-play games for smartphone and tablet devices. Glu is focused on creating compelling original IP games such as CONTRACT KILLER, COOKING DASH, DEER HUNTER, DINER DASH, DINO HUNTER: DEADLY SHORES, ETERNITY WARRIORS, FRONTLINE COMMANDO, RACING RIVALS, TAP SPORTS BASEBALL, and TAP SPORTS FOOTBALL, and branded IP games including KIM KARDASHIAN: HOLLYWOOD, KATY PERRY POP, JAMES BOND: WORLD OF ESPIONAGE, MISSION IMPOSSIBLE: ROGUE NATION and SNIPER X WITH JASON STATHAM on the App Store, Google Play, Amazon Appstore, Facebook, Mac App Store, and Windows Phone. Glu’s unique technology platform enables its titles to be accessible to a broad audience of consumers globally. Founded in 2001, Glu is headquartered in San Francisco with major U.S. offices outside Seattle and in Long Beach, and international locations in Canada, China, India, Japan, Korea, and Russia. Consumers can find high-quality entertainment wherever they see the ‘g’ character logo or at www.glu.com.

For live updates, please follow Glu via Twitter at www.twitter.com/glumobile or become a Glu fan at www.facebook.com/glumobile.

CONTRACT KILLER, COOKING DASH, DEER HUNTER, DINER DASH, DINO HUNTER: DEADLY SHORES, ETERNITY WARRIORS, FRONTLINE COMMANDO, RACING RIVALS, TAP SPORTS BASEBALL, TAP SPORTS FOOTBALL, SNIPER X, GLU, GLU MOBILE, and the ‘g’ character logo are trademarks of Glu Mobile Inc.

Investor Relations:
ICR, Inc.
Seth Potter, 646-277-1230
ir@glu.com

(ATHX) & Healios Enter Into Regenerative Medicine Partnership

Alliance to Focus on Development and Commercialization of Regenerative Medicine Products for Stroke and Other Potential Indications Using New Regulatory Framework in Japan

Contact:
Athersys, Inc.
William (B.J.) Lehmann, J.D.
President and Chief Operating Officer
Tel: (216) 431-9900
Fax: (216) 432-2461
bjlehmann@athersys.com

Healios K.K.
Corporate Communication Group
Tel: 81-(0) 3-5777-8308         
Fax: 81-(0) 3-3434-7231
pr@healios.jp

(CPAH) Leverages Channel Strategy to Focus on Small to Large Enterprise

Company Focuses on Three-Pronged Go-To-Market Strategy to Set the Stage for Further Growth

CounterPath Corporation
Todd Carothers
Executive Vice President of Marketing and Products
tcarothers@counterpath.com

(BIOC) Launches Blood-based Test for Prostate Cancer, Expands Offering in Breast Cancer

Introduction of blood-based assay to detect androgen receptor expression builds on leading position in detecting and monitoring cancer through liquid biopsy

SAN DIEGO, Jan. 7, 2016  — Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing biomarkers to improve the detection and treatment of cancer, announces the launch of the CLIA-validated androgen receptor expression assay using a patient’s blood for the detection and monitoring of late-stage prostate cancer and a certain form of breast cancer.

“This test represents a significant milestone in which we expand into prostate cancer and further demonstrate the versatility of our proprietary liquid biopsy platforms,” said Michael W. Nall, President and CEO of Biocept.  “We continue to build on our leadership position in the emerging liquid biopsy field with commercialized tests for detection and monitoring of lung, breast, colon, gastric and now prostate cancers.”

The Biocept assay uses circulating tumor cells (CTCs) from a simple blood draw to detect androgen receptor expression, which is prevalent in patients with advanced prostate cancer.  Prostate cancer is the second leading cause of male cancer-related death and the second most commonly diagnosed cancer among men in the U.S. with 220,800 cases identified in 2014, according to the American Cancer Society.  Approximately one in every seven men in the U.S. will be diagnosed with prostate cancer during his lifetime.

Androgen receptor is also found in a subset of patients with estrogen receptor negative, progesterone receptor negative and Her2 negative breast cancer, known as triple negative breast cancer.  Triple negative breast cancer accounts for 10-20% of breast cancer patients, who typically have a poorer prognosis than patients with other forms of breast cancer.

“Studying various forms of androgen receptor expression could play a future role in personalized medicine for patients with metastatic prostate cancer, castration-resistant prostate cancer and triple negative breast cancer,” said Veena Singh, MD, Senior Vice President and Senior Medical Director of Biocept. “Androgen receptor expression has a long established role in prostate cancer, with published and ongoing studies examining its status in triple negative breast cancer suggest possible prognostic and predictive value in these patients.”

About Biocept

Biocept, Inc. is a commercial-stage molecular diagnostics company that utilizes a proprietary technology platform and a standard blood sample to provide physicians with important prognostic and predictive information to enhance individual treatment of patients with cancer. Biocept’s patented technology platform captures and analyzes circulating tumor DNA, both in CTCs and in plasma (ctDNA). Biocept currently offers assays for gastric cancer, breast cancer, lung cancer, colorectal cancer, prostate cancer and melanoma, and plans to introduce additional CLIA-validated assays in the near term. For additional information, please visit www.biocept.com.

Forward-Looking Statements Disclaimer Statement

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to our ability to improve the detection and treatment of cancer, the role of androgen receptor expression in personalized medicine and its prognostic and predictive value, our impact on diagnostic strategies, our ability to enhance individual cancer treatments and planned future offerings, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our Securities and Exchange Commission (SEC) filings. The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this release. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law. Readers are advised to review our filings with the SEC, which can be accessed over the Internet at the SEC’s website located at www.sec.gov.

(MMYT) Ctrip Announces Investment in MakeMyTrip

SHANGHAI, Jan. 7, 2016  — Ctrip.com International, Ltd. (NASDAQ: CTRP) (“Ctrip”) today announced that it will invest US$180 million in MakeMyTrip Limited (NASDAQ: MMYT)   (“MakeMyTrip”) , India’s largest online travel company, via convertible bonds. In addition, MakeMyTrip has granted Ctrip permission to acquire MakeMyTrip shares in the open market, so that combined with shares convertible under the convertible bonds, Ctrip may beneficially own up to 26.6% of MakeMyTrip’s outstanding shares. Upon completion of the investment, Ctrip will acquire the right to appoint a director to the MakeMyTrip board of directors.

Deep Kalra, Founder and  Group CEO, MakeMyTrip said, “We are delighted to have Ctrip invest in us. Ctrip is the dominant market leader in the online travel market in China. We believe there are many similarities in the Indian and Chinese online travel markets and we expect this strategic relationship between two market leaders to be mutually beneficial.”

“Today’s announcement marks the beginning of the strategic relationship between Ctrip and MakeMyTrip. Through this transaction, Ctrip has now gained exposure to India’s fast growing online travel market,” said James Liang, Co-founder, Chairman, and CEO of Ctrip.

About Ctrip.com International, Ltd.

Ctrip.com International, Ltd. is a leading travel service provider of accommodation reservation, transportation ticketing, packaged tours, and corporate travel management in China. It is the largest online consolidator of accommodations and transportation tickets in China in terms of transaction volume. Ctrip enables business and leisure travelers to make informed and cost-effective bookings by aggregating comprehensive travel related information and offering its services through an advanced transaction and service platform consisting of its mobile apps, Internet websites and centralized, toll-free, 24-hour customer service center. Ctrip also helps customers book vacation packages and guided tours. In addition, through its corporate travel management services, Ctrip helps corporate clients effectively manage their travel requirements. Since its inception in 1999, Ctrip has experienced substantial growth and become one of the best-known travel brands in China.

For further information, please contact:

Investor Relations

Ctrip.com International, Ltd.
Tel: (+86) 21 3406 4880 X 12300
Email: iremail@ctrip.com

(DVAX) Reports Top Line Results of Phase 3 HEPLISAV-B(TM) Study

BLA Resubmission Targeted for End of Q1 2016; Webcast Conference Call to Review Clinical Data Scheduled for Today at 8:30 am ET

Contact:
Jennifer Williams
Cook Williams Communications, Inc.
360-668-3701
Email contact

Contact:
Michael Ostrach
Chief Financial Officer
510-229-2907
Email contact

(INVT) Amends Patent Purchase Agreement and Reduces Liabilities by $17.3 Million

Amended Agreement Significantly Strengthens Company’s Financial Position

(OGES) Announces New Corporate Image, Branding and Media Communications Tools

MELBOURNE, FL–(Jan 7, 2016) – Oakridge Global Energy Solutions, Inc. (OTCQB: OGES) is pleased to announce its new corporate image, branding and media communications tools in conjunction with its ramp up to full production of its best in class lithium-ion “Proudly Made in USA” batteries and energy storage products.

As a key part of its new corporate image and branding, Oakridge now has a sharp new-look website (www.OakRidgeGlobalEnergy.com) that highlights the company’s global market and presence, and which is in keeping with its corporate mission to become the leading “Made in USA” producer of lithium-ion batteries and energy storage products. The new website now also contains easy-to-access product details for the reference of wholesale consumers and direct customers alike. The revamped site can also be accessed by using Oakridge’s old domain name, www.OakG.net.

Oakridge has also partnered with DreamTeamNetwork (“DTN”) to create an innovative Investor relations (IR) package that provides excellent detail for potential customers and investors regarding the company and its products.

This new IR package can be viewed at http://OGES.QualityStocks.net/ir/

“Having successfully completed a total revamp of the company’s business and products during 2014 and 2015, Oakridge continues to improve every aspect of its business, and media and communications tools like these are no exception,” says OGES executive chairman and CEO Steve Barber. “These new tools are fantastically well-designed and provide improved information regarding all aspects of our business. The new website and IR package provide Oakridge with a major point of differentiation over our competitors in the Far East, and these media and communications tools that we have just launched are absolutely best in class. Being in the battery business, we have reviewed websites from over 100 companies that are in the industry worldwide. Investors and customers demand easy access and good communication and we again lead the industry by delivering these tools.”

The new branding also addresses increasing interest and demand for information on Oakridge’s revolutionary energy storage technology.

“This new corporate image and branding, embodied in the dramatic, crisp new website and the matching investor relations package were inspired by requests and questions from our various customers, investors and suppliers about the company and its game-changing ‘Made in USA’ lithium-ion battery and energy storage products,” said vice president of Oakridge Corporate Communications Suzanna Barber. “Our goal is to be a global leader in all aspects of the world battery market, and our new media and communications tools are a key part in that process of getting the exciting Oakridge message out and allowing Oakridge to take its rightful place in the global marketplace.”

DTN Managing Director Mike McCarthy adds, “We’ve worked closely with Oakridge for several months now and are increasingly impressed with the company’s technology, vision, and capability to execute its expansion strategies. Management is a pleasure to work with and we’re proud to put our name and resources behind the Oakridge brand. The sleek new website and factual IR kit demonstrate Oakridge’s commitment to clear communication and presentation.”

Oakridge continues to grow and expand as planned. During 2015 and into 2016 Oakridge has continued to exceed targets for hiring of employees, acquisition of capital equipment for factory automation, and providing innovative and informative tools to keep stakeholders fully engaged in company activities. This is another example of how this “Proudly Made In The USA” manufacturing company is aggressively serving its target markets. Oakridge is fully engaging with the world lithium battery market in every aspect. The new 69,000-square-foot facility at 3520 Dixie Highway in Melbourne, Florida, is now fully operational with production ramping up rapidly since reopening after the Christmas period on January 4. Oakridge will also be attending several major industry trade shows in the first quarter of 2016 to roll out exiting new products.

About Oakridge Global Energy Solutions, Inc.

Oakridge Global Energy Solutions Inc. is a publicly traded company, trading symbol: OGES on the OTCQB with a market capitalization of approximately USD $ 250,000,000, whose primary business is the development, manufacturing and marketing of energy storage products. Additional information can be accessed on the company’s website www.oakridgeglobalenergy.com

Forward-Looking Statements Disclaimer: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements are not a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time the statements are made and involve known and unknown risks, uncertainties and other factors that may cause our results, levels of activity, performance or achievements to be materially different from the information expressed or implied by the forward-looking statements in this press release. This press release should be considered in light of all filings of the Company that are contained in the Edgar Archives of the Securities and Exchange Commission at www.sec.gov.